We are live on ! Find out more
PGNX

Progenics Pharmaceuticals Inc
PGNX

Delisted

PGNX was delisted on the 19th of June, 2020.

Back to rankings

142 hedge funds and large institutions have $415M invested in Progenics Pharmaceuticals Inc in 2019 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 47 increasing their positions, 43 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more call options, than puts

Call options by funds: $2.69M | Put options by funds: $1.16M

31% more capital invested

Capital invested by funds: $317M → $415M (+$97.3M)

9% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 43

4% less funds holding

Funds holding: 148 → 142 (-6)

14% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 21

Holders
142
Holders Change
-6
Holders Change %
-4.05%
% of All Funds
3.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
47
Reduced
43
Closed
21
Calls
$2.69M
Puts
$1.16M
Net Calls
+$1.53M
Net Calls Change
+$1.82M

Top Buyers

Rank Fund Capital Flow
1
FCM
Farallon Capital Management
California
+$6.47M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$4.73M
3
HCMT
Highland Capital Management (Texas)
Texas
+$3.46M
4
N
Nuveen
North Carolina
+$3.06M
5
JGC
J. Goldman & Co
New York
+$1.93M

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$3.88M
2
Deutsche Bank
Deutsche Bank
Germany
-$3.7M
3
AAP
Ardsley Advisory Partners
Connecticut
-$2.92M
4
Wells Fargo
Wells Fargo
California
-$2.21M
5
Citadel Advisors
Citadel Advisors
Florida
-$2.21M
Name Holding Trade Value Shares
Change 		Change in
Stake
FI
26
Fosun International
China
$2.75M – – –
JGC
27
J. Goldman & Co
New York
$2.47M +$1.93M +400,000 New
Bank of America
28
Bank of America
North Carolina
$2.31M -$1.55M -322,303 -46%
PPA
29
Parametric Portfolio Associates
Washington
$1.74M +$383K +79,392 +39%
RhumbLine Advisers
30
RhumbLine Advisers
Massachusetts
$1.59M +$79.9K +16,567 +7%
Allianz Asset Management
31
Allianz Asset Management
Germany
$1.57M +$51.3K +10,644 +4%
Barclays
32
Barclays
United Kingdom
$1.41M +$478K +99,173 +76%
Legal & General Group
33
Legal & General Group
United Kingdom
$1.22M – – –
Public Sector Pension Investment Board (PSP Investments)
34
Public Sector Pension Investment Board (PSP Investments)
Quebec, Canada
$1.15M +$547K +113,400 +154%
Rafferty Asset Management
35
Rafferty Asset Management
New York
$1.13M -$59.4K -12,328 -6%
AA
36
ALPS Advisors
Colorado
$1.09M -$129K -26,824 -13%
Swiss National Bank
37
Swiss National Bank
Switzerland
$951K – – –
Susquehanna International Group
38
Susquehanna International Group
Pennsylvania
$928K +$725K +150,453 New
New York State Common Retirement Fund
39
New York State Common Retirement Fund
New York
$894K -$1.59K -330 -0.2%
PP
40
PDT Partners
New York
$863K -$59.3K -12,300 -8%
New York State Teachers Retirement System (NYSTRS)
41
New York State Teachers Retirement System (NYSTRS)
New York
$856K – – –
AllianceBernstein
42
AllianceBernstein
Tennessee
$854K +$205K +42,500 +44%
WVP
43
Worth Venture Partners
New Jersey
$853K – – –
Citigroup
44
Citigroup
New York
$847K +$339K +70,412 +105%
Prudential Financial
45
Prudential Financial
New Jersey
$825K +$4.3K +893 +0.7%
ASRS
46
Arizona State Retirement System
Arizona
$811K +$4.99K +1,035 +0.8%
California State Teachers Retirement System (CalSTRS)
47
California State Teachers Retirement System (CalSTRS)
California
$808K +$8.56K +1,775 +1%
ERSOT
48
Employees Retirement System of Texas
Texas
$784K -$400K -83,000 -40%
California Public Employees Retirement System
49
California Public Employees Retirement System
California
$727K -$55.4K -11,500 -9%
Squarepoint
50
Squarepoint
New York
$712K -$154K -32,015 -22%
1
2
3 4 5

PGNX Hedge Fund Activity: Q2 2019 in Review

142 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q2 2019, worth a combined $415M — up 31% from $317M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of PGNX and 18 opened new positions — a net loss of 3 holders — while 43 trimmed existing stakes and 47 added.

The largest buyer was Farallon Capital Management, adding an estimated $6.47M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $3.88M sold.

  • 142 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q2 2019, down from 148 in Q1 2019.
  • Funds reported $415M of Progenics Pharmaceuticals Inc stock for Q2 2019, up 31% quarter-over-quarter.
  • 18 funds opened new Progenics Pharmaceuticals Inc positions in Q2 2019 and 21 closed out, a net change of -3 holders.
  • The largest Progenics Pharmaceuticals Inc buyer in Q2 2019 was Farallon Capital Management, an estimated $6.47M added.
  • The largest Progenics Pharmaceuticals Inc seller in Q2 2019 was Renaissance Technologies, an estimated $3.88M sold.

Based on aggregated 13F filings for Q2 2019.